Skip to main content
OpenTrials

Clinical trial condition

Head and Neck Neoplasms

Explore clinical trials studying Head and Neck Neoplasms. Study availability and eligibility vary by location and protocol.

3,749 public trials 1,058 recruiting studies
Refine in advanced search Browse all conditions

Head and Neck Neoplasms trial results

Recruiting

Integrated Cancer Repository for Cancer Research

NCT02012699

Conditions
Abdominal Neoplasms, Adenoma, Adenomatous Polyposis Coli, +195 more
Locations
  • Advent Health Greenwood Village, Colorado, United States
  • Hartford HealthCare Cancer Institute at Manchester Medical Hospital Manchester, Connecticut, United States
  • Florida Hospital Memorial Medical Center Daytona Beach, Florida, United States
  • Florida Hospital DeLand DeLand, Florida, United States
View all 42 locations
View Trial Details
Recruiting

EMR Versus ESD for Barrett's Neoplasia

NCT05276791

Conditions
Barrett Adenocarcinoma, Barrett Esophagus, Barretts Esophagus With Dysplasia, +11 more
Locations
  • Amsterdam University Medical Center Amsterdam, Netherlands
  • Catharina Ziekenhuis Eindhoven, Netherlands
  • University Medical Center Groningen Groningen, Netherlands
  • St. Antonius Ziekenhuis Nieuwegein, Netherlands
View Trial Details
Recruiting

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

NCT06747585

Conditions
Carcinoma, Carcinoma, Squamous Cell, Cervical Squamous Cell Carcinoma, +16 more
Locations
  • Mayo Foundation for Medical Education and Research - Mayo Cl Scottsdale, Arizona, United States
  • Providence Medical Foundation Fullerton, California, United States
  • USC Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Yale Comprehensive Cancer Center New Haven, Connecticut, United States
View all 41 locations
View Trial Details
Recruiting

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

NCT05319730

Conditions
Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +13 more
Locations
  • University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927) Tucson, Arizona, United States
  • UCLA Hematology/Oncology - Santa Monica ( Site 4905) Los Angeles, California, United States
  • Hematology-Oncology Associates of Central NY, P.C. ( Site 4925) East Syracuse, New York, United States
  • Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 4907) New York, United States
View all 59 locations
View Trial Details
Recruiting

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

NCT06532279

Conditions
Carcinoma, Carcinoma, Squamous Cell, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, +62 more
Locations
  • Arizona Center for Cancer Care - Gilbert Gilbert, Arizona, United States
  • Arizona Center for Cancer Care-Peoria Peoria, Arizona, United States
  • Arizona Center for Cancer Care - Phoenix Phoenix, Arizona, United States
  • Arizona Center for Cancer Care - Scottsdale Scottsdale, Arizona, United States
View all 153 locations
View Trial Details
Recruiting

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

NCT04333537

Conditions
Buccal Mucosa Squamous Cell Carcinoma, Carcinoma, Carcinoma, Squamous Cell, +20 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 107 locations
View Trial Details
Recruiting

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

NCT05408845

Conditions
Head and Neck Neoplasms, Metastatic Salivary Gland Carcinoma, Mouth Diseases, +10 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Kaiser Permanente Dublin Dublin, California, United States
  • Kaiser Permanente-Fremont Fremont, California, United States
View all 152 locations
View Trial Details

Related conditions